Search clinical trials for: METADOXINE

Total 14 results

University of Pennsylvania

Recruiting

Multi-System Analysis of Opioid Receptor Binding

Healthy

United States
Hospital General de Mexico

Withdrawn

Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis

Mexico
Instituto Nacional de Ciencias Medicas y Nutricion...

Unknown

Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis

NAFLD | Pre-diabetes

Mexico
GlaxoSmithKline

Completed

Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy

Benign Prostatic Hyperplasia
Alcobra Ltd.

Completed

A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )

ADHD | Attention-Deficit/Hyperactivity Disorder, Predominantly Inattentive Type

United States, Israel
Alcobra Ltd.

Completed

Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

Attention Deficit Hyperactivity Disorder

Israel
Alcobra Ltd.

Completed

A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

Fragile X Syndrome

United States, Israel
Brown University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

A Novel Pharmacotherapy for Alcoholism and Alcohol Liver Disease

Alcoholic Liver Disease | Alcoholism,

United States
PharmaKing

Completed

Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

Alcoholic Hepatitis | Alcoholic Fatty Liver Disease

Korea, Republic of
Alcobra Ltd.

Completed

Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects

ADHD, Predominantly Inattentive Type

Israel
Hospital General de Mexico

Completed

Metadoxine as a Therapy for Severe Alcoholic Hepatitis

Severe Alcoholic Hepatitis

Mexico
Alcobra Ltd.

Completed

Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder

ADHD Predominantly Inattentive Type

Israel
Alcobra Ltd.

Completed

A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers

Healthy Adult Subjects

Israel
Alcobra Ltd.

Completed

Clinical Efficacy & Safety, of Metadoxine (MG01CI) Extended Release in Attention-Deficit Hyperactivity Disorder (ADHD)

ADHD

Israel

3

Subscribe